Van Oene Mark
Known title: Chief Operating OfficerCIK: 0001707477
Associated companies
Transaction History
| PACB | ▼ Sell | Open Market | 26,911 | $30K | 8/17/2026 | View on chart |
| PACB | ▲ Buy | Grant | 489,130 | $0 | 8/10/2026 | View on chart |
| PACB | ▼ Sell | Open Market | 6,504 | $10K | 3/3/2026 | View on chart |
| PACB | ▲ Buy | Grant | 500,000 | $0 | 2/27/2026 | View on chart |
| PACB | ▼ Sell | Open Market | 55,107 | $90K | 2/18/2026 | View on chart |
| PACB | ▼ Sell | Open Market | 129,790 | $205K | 2/17/2026 | View on chart |
| PACB | ▼ Sell | Open Market | 26,836 | $35K | 8/18/2025 | View on chart |
| PACB | ▲ Buy | Grant | 449,176 | $0 | 3/19/2025 | View on chart |
| PACB | ▼ Sell | Open Market | 6,486 | $9K | 3/3/2025 | View on chart |
| PACB | ▼ Sell | Open Market | 100,773 | $189K | 2/18/2025 | View on chart |
| PACB | ▼ Sell | Open Market | 34,405 | $70K | 1/10/2025 | View on chart |
| PACB | ▼ Sell | Open Market | 38,011 | $63K | 8/16/2024 | View on chart |
| PACB | ▼ Sell | Open Market | 9,186 | $45K | 3/4/2024 | View on chart |
| PACB | ▲ Buy | Grant | 798,076 | $0 | 2/22/2024 | View on chart |
| PACB | ▼ Sell | Open Market | 33,560 | $200K | 2/16/2024 | View on chart |
| PACB | ▼ Sell | Open Market | 31,012 | $241K | 1/9/2024 | View on chart |
| PACB | ▼ Sell | Open Market | 26,102 | $287K | 8/16/2023 | View on chart |
| PACB | ▼ Sell | Open Market | 6,268 | $60K | 3/3/2023 | View on chart |
| PACB | ▲ Buy | Grant | 328,500 | $0 | 3/2/2023 | View on chart |
| PACB | ▼ Sell | Open Market | 26,722 | $255K | 1/10/2023 | View on chart |
| PACB | ▲ Buy | Grant | 300,000 | $0 | 8/25/2022 | View on chart |
| PACB | ▲ Buy | Grant | 72,500 | $0 | 3/2/2022 | View on chart |
| PACB | ▼ Sell | Open Market | 41,480 | $590K | 1/11/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
PACB Pushes HiFi Sequencing for Clinical Growth
Pacific Biosciences is focusing on its HiFi sequencing technology to drive clinical adoption and achieve $40 million in savings. This strategic push aims to address the company's ongoing profitability challenges while targeting long-term growth. The stock recently saw a volume spike and touched its 200-day moving average, reflecting heightened market interest in these operational updates.
PACB Pushes HiFi Sequencing for Clinical Growth. Pacific Biosciences is focusing on its HiFi sequencing technology to drive clinical adoption and achieve $40 million in savings. This strategic push aims to address the company's ongoing profitability challenges while targeting long-term growth. The stock recently saw a volume spike and touched its 200-day moving average, reflecting heightened market interest in these operational updates.